SynthesisMolecular neurodegeneration2021
Brain mechanisms underlying neuropsychiatric symptoms in Alzheimer's disease: a systematic review of symptom-general and -specific lesion patterns.
Synthesis in Molecular neurodegeneration, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 112 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
112 citing papers in PubMed, 5 syntheses or guidelines pooled it, 207 citations in OpenAlex.
- Efficacy and Safety of Cannabinoids for Neuropsychiatric Symptoms of Dementia: A Systematic Review with Meta-analysis.CNS drugs · 2026Pooled it
- Structural Neuroimaging Correlates of Neuropsychiatric Symptoms in Alzheimer's Disease: A Systematic Literature Review.Dementia and geriatric cognitive disorders · 2025Pooled it
- Efficacy of methylphenidate for the treatment of apathy in patients with Alzheimer's disease: a systematic review and meta-analysis of randomized controlled studies.Psychopharmacology · 2022Pooled it
- Neuropsychiatric Inventory domains cluster into neuropsychiatric syndromes in Alzheimer's disease: A systematic review and meta-analysis.Brain and behavior · 2022Pooled it
- Cerebral Volumetric Correlates of Apathy in Alzheimer's Disease and Cognitively Normal Older Adults: Meta-Analysis, Label-Based Review, and Study of an Independent Cohort.Journal of Alzheimer's disease : JAD · 2022Pooled it
- Electroacupuncture for treating the cognitive symptoms of Alzheimer's disease: a randomized controlled trial.Frontiers in psychiatry · 2026Trial
- A multi-modal medical management and lifestyle intervention increase cerebral blood flow and lowers diabetic risk in persons with early Alzheimer's disease: Mid-trial results from the PREVENTION trial.Journal of Alzheimer's disease : JAD · 2025Trial
- Positive affect disrupts neurodegeneration effects on cognitive training plasticity in older adults.Social cognitive and affective neuroscience · 2024Trial
- AI-based characterization of Alzheimer's disease phenotypes from population-scale single-cell data.Nature medicine · 2026Article
- Ursolic acid reduces Aβ-driven aggression via Gab1-mediated autophagy and dorsal hippocampal circuit modulation in Alzheimer's disease.Journal of advanced research · 2026Article
- LC-MS-based metabolomics reveals the In Vivo effects of cognitive formula 1 in rats with Aβ-induced Alzheimer's disease.Experimental brain research · 2026Article
- Article
- Age-Associated Behavioral Alterations in Laboratory-Housed Octodon degus.bioRxiv : the preprint server for biology · 2026Article
- Morbidity and medication use preceding a diagnosis of late-onset Alzheimer's disease: a Danish nationwide study.Journal of neurology · 2026Article
- Combined Influence of Subjective Cognitive Complaints and Neuropsychiatric Symptoms on Cognitive Trajectories in Older Adults.Brain sciences · 2026Article
- Facial phenotypes in Alzheimer's disease: from neurobiology to artificial intelligence.Alzheimer's research & therapy · 2026Review
- Plasma neurofilament light chain and regional brain atrophy mediate the association of neuropsychiatric symptoms with cognition in Alzheimer's disease: evidence from two population-based studies.Psychological medicine · 2026Article
- Lecanemab Reduces Neuropsychiatric Symptoms and Related Regional Brain Amyloid Load in Early Alzheimer's Disease: A Preliminary Prospective Study.CNS neuroscience & therapeutics · 2026Article
- The emergence of neuropsychiatric symptoms in preclinical Alzheimer's disease: An emotion regulation perspective.Neuron · 2026Review
- Decoupling MCI-specific signatures from shared neurobiological substrates of cognitive aging via deep learning.NPJ digital medicine · 2026Article
52 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Neuropsychiatric symptoms (NPSs) are common in patients with Alzheimer's disease (AD) and are associated with accelerated cognitive impairment and earlier deaths. This review aims to explore the neural pathogenesis of NPSs in AD and its association with the progression of AD. We first provide a literature overview on the onset times of NPSs. Different NPSs occur in different disease stages of AD, but most symptoms appear in the preclinical AD or mild cognitive impairment stage and develop progressively. Next, we describe symptom-general and -specific patterns of brain lesions. Generally, the anterior cingulate cortex is a commonly damaged region across all symptoms, and the prefrontal cortex, especially the orbitofrontal cortex, is also a critical region associated with most NPSs. In contrast, the anterior cingulate-subcortical circuit is specifically related to apathy in AD, the frontal-limbic circuit is related to depression, and the amygdala circuit is related to anxiety. Finally, we elucidate the associations between the NPSs and AD by combining the onset time with the neural basis of NPSs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.